Michael Spinner

Has grant

Clinical Assistant Professor of Medicine (Hematology/Oncology)

University of California, San Francisco

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Spinner is a Clinical Assistant Professor of Medicine (Hematology/Oncology) at the University of California, San Francisco. His research interests focus on lymphoma treatment, including diffuse large B-cell lymphoma and Hodgkin lymphoma, with recent contributions to the understanding of outcomes related to various therapeutic approaches. Additionally, he is involved in studying autoimmune lymphoproliferative syndromes and the effects of GATA2 deficiency. Dr. Spinner's work aims to improve clinical outcomes for patients through evidence-based research and collaborative studies.

Recent Grants

Grant: Close

A phase 2 study of magrolimab and pembrolizumab in relapsed or refractory classic Hodgkin lymphoma

Open Date: 2020-07-01

Close Date: 2021-06-01

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Spinner

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.

Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease.

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.

Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.

Pulmonary Manifestations of GATA2 Deficiency.

CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.

Collaborators (6)

Neil Bailey

Daniel Reed

Muhammad Hamid

Yago Nieto

David Bond

Christopher Strouse

Make your next move.